Financial Shenanigans

Financial Shenanigans

The reported numbers at Elevance Health are not fictional, but they are flattering. Reported 2025 adjusted EPS of $30.29 was confirmed by management to include roughly $3.75 per share of nonrecurring tailwinds (largely a discrete tax benefit), and yet operating cash flow still fell to $4.29B — only 0.76 times GAAP net income, the worst ratio in at least eight years. A $935M Medicare risk-adjustment accrual disclosed in Q1 2026 for historical CMS data disputes, plus a federal False Claims Act complaint filed against the company on May 1, 2025, sit on top of a slow-burn working-capital build that has absorbed billions of dollars of cash over five years. The income statement is not the problem; the cash and contingency disclosures are.

1. The Forensic Verdict

Risk grade: Elevated (52/100). The accounting itself appears in line with industry conventions and the auditor (Ernst & Young) signed a clean opinion — but the gap between reported earnings and economic cash generation has widened materially, recurring "non-recurring" charges average over $1.5B per year, and two unresolved exogenous risks (the DOJ broker-kickback complaint and the $935M CMS risk-adjustment accrual) cap how confident an investor should be in trailing earnings. The single data point that would most change the grade is whether 2026 operating cash flow rebounds to at least 1.0× net income as guided ($5.5B+); a second consecutive year below 1.0× would push this to High.

The scorecard concentrates risk in three places: cash-flow quality (working-capital lifeline), key-metric hygiene (non-GAAP gap, adjusted EPS flattered by tax benefits), and balance-sheet metrics (the discontinuous step-up in days-in-claims-payable in Q1 2026). Income-statement timing tests are clean; the issues are in disclosure, normalization, and contingency.

2. Breeding Ground

The governance backdrop is strong on most measurable axes. EY has been auditor since 2002 — long tenure is a yellow flag, partially offset by the audit committee's 2025 RFP that re-confirmed EY after a competitive process. Audit fees of $17.96M against $0.73M of tax fees and zero "all other" fees give a healthy ratio (audit ~82% of total). Say-on-pay passed at 92% in 2025. There is no material weakness, no late filing, no auditor resignation, and no qualified opinion in the file. Insider activity is moderately negative (~$60M open-market sells against ~$3.7M buys over the past year), but CEO Boudreaux executed an open-market buy of about $2.4M in July 2025 after the Medicaid reset — a positive personal-conviction signal that partially offsets the broader sale tilt.

The breeding ground does not amplify the financial-statement risks: governance is conventional and reasonably strong. It also does not dampen them, because two specific elements push the wrong way — incentive compensation runs primarily on adjusted (non-GAAP) measures, and management continues to anchor the long-term algorithm at 12% adjusted EPS growth despite a 2026 guide ($25.50 minimum) that implies an outright decline once the FY2025 nonrecurring tailwinds are stripped out. Pressure to keep the algorithm intact creates the incentive to lean on adjustments and reserve releases.

3. Earnings Quality

Reported earnings are increasingly less representative of underlying economics. Operating margin has compressed every year since FY2019 (5.49% then; 3.33% in FY2025) while the gap between adjusted and GAAP EPS has remained stubbornly above 20%. The single most flattering item in FY2025 is the effective tax rate of 15.6%, down from 24.5% — a discrete non-operating benefit from internal restructuring of subsidiaries that management explicitly called out. Strip that and the GAAP earnings line falls toward $5.0B rather than $5.66B.

Operating margin has fallen 222 bps over seven years. The FY2025 net margin held up only because the effective tax rate dropped 890 bps in a single year — a one-off help that reverses next period unless the restructuring is repeatable.

Three of these five buckets recur every year ($236M of "transaction and integration" in FY2025 is the eighth consecutive year of similar charges; intangible amortization is structural to the M&A model; financial-instrument losses have averaged $597M per year). Truly nonrecurring add-backs are smaller than they look. The total non-GAAP gap was $1,142M in FY2025 — about 20% of GAAP net income.

Management explicitly acknowledged on the Q4 2025 call that approximately $3.75 per share of FY2025 adjusted EPS was nonrecurring (primarily a discrete tax benefit). The underlying figure of about $26.54 sits below the FY2024 baseline of $33.04 and lines up much more naturally with the 2026 guide of "at least $25.50". The reset is real; the trailing P/E should be calculated against $26.50, not $30.29. This is a yellow-to-red signal on key-metric hygiene — investors who anchor on $30.29 are over-paying for trailing earnings.

Receivables growth tracked revenue closely in FY2025 (13.0% vs 12.8%), so income-statement timing tests are clean. The earnings-quality risk is concentrated in the size and durability of adjustments, not premature revenue recognition.

4. Cash Flow Quality

This is where the picture gets sharper. Operating cash flow has fallen from $10.7B (FY2020) to $4.3B (FY2025) — a 60% decline — while net income has risen 24% over the same period. The CFO/NI ratio, which routinely sits at 1.3x-1.4x for a healthy managed-care insurer, has dropped to 0.76x in FY2025 (the worst since at least FY2018) and was already at 0.97x in FY2024. The lifeline that used to support cash generation — payables and float — has reversed.

FCF/NI of 0.56x in FY2025 is the canary. A managed-care insurer earning $1 of GAAP profit normally produces $1.10-$1.30 of free cash because reserves and float run in the company's favor. The fact that ELV is now generating only $0.56 of FCF per dollar of net income means earnings are being booked faster than the cash arrives.

Receivables doubled in five years — from $11.0B to $21.5B — while revenue grew 64%. DSO drifted from 33d to 40d (a 7-day move, equivalent to about $3.6B of cash absorbed into working capital that would otherwise have shown up as CFO). Days payable outstanding moved the wrong way (18d → 15d), meaning ELV is paying providers faster, accelerating cash out the door. The cash conversion cycle widened from 14 days to 22 days. None of this is fraud — but it is a clear "unsustainable working-capital lifeline reversed" pattern: the working-capital tailwind that flattered prior CFO has turned into a headwind.

In FY2024 the company spent $4.81B on acquisitions, paid $1.51B of dividends, and bought back $2.90B of stock — total cash out of $9.22B against operating cash flow of only $5.81B. Free cash flow after acquisitions was negative $257M. The $4.4B of capital return that year was funded by a $7.7B debt issuance, not by earnings. In FY2025 the M&A line reversed slightly (a small $88M inflow, suggesting a disposal or earn-out unwind), and capital returned to shareholders ($4.13B) again exceeded FCF ($3.17B). Long-term debt has risen from $19.3B (FY2020) to $30.8B (FY2025) — a 60% increase — to keep the capital-return programme intact while organic cash production has weakened.

5. Metric Hygiene

Management leans heavily on adjusted measures — Adjusted Shareholders Net Income, Adjusted EPS, Adjusted Operating Expense Ratio, Operating Gain — and pays incentive compensation on the adjusted versions. The reconciliations are disclosed, but several "non-recurring" items recur with metronome regularity, which is the central definitional concern.

The favorable prior-year reserve releases — a recurring contributor to MCR — fell from 12.3% of opening claims payable in FY2024 to 9.0% in FY2025. That is the smallest cushion in three years, and it appeared even as the absolute dollar figure stayed near $1.29B. Compounding this, the company recognized $935M post-period in Q1 2026 for historical CMS risk-adjustment data disputes — pushing days-in-claims-payable from 41.3 to 46.6. The combined picture: the reserve cushion was thinning at year-end, then a large new accrual was layered on three months later. That sequence raises the question of whether some portion of the $935M should have been accrued earlier.

6. What to Underwrite Next

The forensic risk is real but contained. It is not a thesis breaker. It is a valuation haircut and a position-sizing limiter. Five things drive the diligence list.

The decisive paragraph. Elevance Health's FY2025 numbers are not faked, but they are dressed up. The headline adjusted EPS overstates underlying earning power by about 12% once management's own confirmed nonrecurring tax tailwind is removed. Operating cash flow has fallen below 80% of net income for two consecutive years — a regime change for this business model — while capital returned to shareholders has been propped up by net new debt. Two contingencies (the DOJ False Claims Act complaint, and the $935M post-period CMS risk-adjustment accrual whose ultimate exposure is disclosed as a nine-figure range in either direction) sit outside the FY2025 income statement but inside the underwriting case. None of this rises to fraud, restatement, or auditor concern, and the breeding ground (governance, audit fees, board) is conventional. The right response is to value ELV on a normalized $26-27 EPS rather than $30.29, demand a haircut for the cash-flow gap, and treat the position as size-limited until CFO/NI rebounds and Q1 2026's accrual stabilizes.